Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Simon Tiberi; M. C. Payen; Giovanni Sotgiu; L. D'Ambrosio; Valentina Alarcon Guizado; Jan Willem C Alffenaar; Marcos Abdo Arbex; Jose A. Caminero; Rosella Centis; Saverio De Lorenzo; Mina Gaga; Gina Gualano; Aurora Jazmín Roby Arias; Anna Scardigli; Alena Skrahina; Ivan Solovic; Giorgia Sulis; Marina Tadolini; Onno W. Akkerman; Edith Alarcon Arrascue; Alena Aleska; Vera Avchinko; Eduardo Henrique Bonini; Félix Antonio Chong Marín; Lorena Collahuazo López; Gerard De Vries; Simone Dore; H. Kunst; Alberto Matteelli; Charalampos Moschos; Fabrizio Palmieri; Apostolos Papavasileiou; Antonio Spanevello; Dante Vargas Vasquez; Pietro Viggiani; Veronica White; Alimuddin Zumla; Giovanni Battista Migliori

doi:10.1183/13993003.02146-2015

Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Simon Tiberi, M. C. Payen, Giovanni Sotgiu, L. D'Ambrosio, Valentina Alarcon Guizado, Jan Willem C Alffenaar, Marcos Abdo Arbex, Jose A. Caminero, Rosella Centis, Saverio De Lorenzo, Mina Gaga, Gina Gualano, Aurora Jazmín Roby Arias, Anna Scardigli, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Onno W. Akkerman, Edith Alarcon ArrascueAlena Aleska, Vera Avchinko, Eduardo Henrique Bonini, Félix Antonio Chong Marín, Lorena Collahuazo López, Gerard De Vries, Simone Dore, H. Kunst, Alberto Matteelli, Charalampos Moschos, Fabrizio Palmieri, Apostolos Papavasileiou, Antonio Spanevello, Dante Vargas Vasquez, Pietro Viggiani, Veronica White, Alimuddin Zumla, Giovanni Battista Migliori

Research output: Contribution to journal › Article › peer-review

Abstract

No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p

Original language	English
Pages (from-to)	1235-1243
Number of pages	9
Journal	Acta tuberculosea Scandinavica
Volume	47
Issue number	4
DOIs	https://doi.org/10.1183/13993003.02146-2015
Publication status	Published - Apr 1 2016

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/13993003.02146-2015

Cite this

Tiberi, S., Payen, M. C., Sotgiu, G., D'Ambrosio, L., Guizado, V. A., Alffenaar, J. W. C., Arbex, M. A., Caminero, J. A., Centis, R., De Lorenzo, S., Gaga, M., Gualano, G., Arias, A. J. R., Scardigli, A., Skrahina, A., Solovic, I., Sulis, G., Tadolini, M., Akkerman, O. W., ... Migliori, G. B. (2016). Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Acta tuberculosea Scandinavica, 47(4), 1235-1243. https://doi.org/10.1183/13993003.02146-2015

Tiberi, S, Payen, MC, Sotgiu, G, D'Ambrosio, L, Guizado, VA, Alffenaar, JWC, Arbex, MA, Caminero, JA, Centis, R, De Lorenzo, S, Gaga, M, Gualano, G, Arias, AJR, Scardigli, A, Skrahina, A, Solovic, I, Sulis, G, Tadolini, M, Akkerman, OW, Arrascue, EA, Aleska, A, Avchinko, V, Bonini, EH, Marín, FAC, López, LC, De Vries, G, Dore, S, Kunst, H, Matteelli, A, Moschos, C, Palmieri, F, Papavasileiou, A, Spanevello, A, Vasquez, DV, Viggiani, P, White, V, Zumla, A & Migliori, GB 2016, 'Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB', Acta tuberculosea Scandinavica, vol. 47, no. 4, pp. 1235-1243. https://doi.org/10.1183/13993003.02146-2015

@article{433461673d004bf29dbd02bb8bd1de41,

title = "Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB",

abstract = "No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p",

author = "Simon Tiberi and Payen, {M. C.} and Giovanni Sotgiu and L. D'Ambrosio and Guizado, {Valentina Alarcon} and Alffenaar, {Jan Willem C} and Arbex, {Marcos Abdo} and Caminero, {Jose A.} and Rosella Centis and {De Lorenzo}, Saverio and Mina Gaga and Gina Gualano and Arias, {Aurora Jazm{\'i}n Roby} and Anna Scardigli and Alena Skrahina and Ivan Solovic and Giorgia Sulis and Marina Tadolini and Akkerman, {Onno W.} and Arrascue, {Edith Alarcon} and Alena Aleska and Vera Avchinko and Bonini, {Eduardo Henrique} and Mar{\'i}n, {F{\'e}lix Antonio Chong} and L{\'o}pez, {Lorena Collahuazo} and {De Vries}, Gerard and Simone Dore and H. Kunst and Alberto Matteelli and Charalampos Moschos and Fabrizio Palmieri and Apostolos Papavasileiou and Antonio Spanevello and Vasquez, {Dante Vargas} and Pietro Viggiani and Veronica White and Alimuddin Zumla and Migliori, {Giovanni Battista}",

year = "2016",

month = apr,

day = "1",

doi = "10.1183/13993003.02146-2015",

language = "English",

volume = "47",

pages = "1235--1243",

journal = "European Journal of Respiratory Diseases",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "4",

}

TY - JOUR

T1 - Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

AU - Tiberi, Simon

AU - Payen, M. C.

AU - Sotgiu, Giovanni

AU - D'Ambrosio, L.

AU - Guizado, Valentina Alarcon

AU - Alffenaar, Jan Willem C

AU - Arbex, Marcos Abdo

AU - Caminero, Jose A.

AU - Centis, Rosella

AU - De Lorenzo, Saverio

AU - Gaga, Mina

AU - Gualano, Gina

AU - Arias, Aurora Jazmín Roby

AU - Scardigli, Anna

AU - Skrahina, Alena

AU - Solovic, Ivan

AU - Sulis, Giorgia

AU - Tadolini, Marina

AU - Akkerman, Onno W.

AU - Arrascue, Edith Alarcon

AU - Aleska, Alena

AU - Avchinko, Vera

AU - Bonini, Eduardo Henrique

AU - Marín, Félix Antonio Chong

AU - López, Lorena Collahuazo

AU - De Vries, Gerard

AU - Dore, Simone

AU - Kunst, H.

AU - Matteelli, Alberto

AU - Moschos, Charalampos

AU - Palmieri, Fabrizio

AU - Papavasileiou, Apostolos

AU - Spanevello, Antonio

AU - Vasquez, Dante Vargas

AU - Viggiani, Pietro

AU - White, Veronica

AU - Zumla, Alimuddin

AU - Migliori, Giovanni Battista

PY - 2016/4/1

Y1 - 2016/4/1

N2 - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p

AB - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p

UR - http://www.scopus.com/inward/record.url?scp=84964054940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964054940&partnerID=8YFLogxK

U2 - 10.1183/13993003.02146-2015

DO - 10.1183/13993003.02146-2015

M3 - Article

VL - 47

SP - 1235

EP - 1243

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 4

ER -

Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this